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ABSTRACT 
Background and aims: Endosonography-guided fine needle aspiration (EUS-FNA) 
is imperfect in diagnosing solid pancreatic lesions (SPL) and subepithelial lesions 
(SEL) including gastrointestinal stromal tumors (GIST). In GISTs, imatinib therapy is 
effective only in variants of oncogenes KIT and PDGFRA. The global aim was to 
improve the EUS-diagnostics and study a biopsy approach (EUS-FNB) to obtain a 
reliable diagnosis of SPLs and SELs. In GISTs, the aim was to evaluate pretreatment 
samples for tumor risk assessment and the guidance of down-sizing imatinib therapy.                        
Methods: In two prospective, single-center studies (2012-2015), SPLs (n=68,Paper I) 
and SELs (n=70,Paper II) were sampled with EUS-FNA and EUS-FNB. A reference 
cohort (2006-2011) was used for comparison. The FNB-tissue of all GISTs (n=44) was 
subjected to Ki-67-indexing and DNA-sequencing of KIT and PDGFRA (Paper III). 
In a last study (Paper IV), pretreatment sequencing of GISTs (n=59) was performed. 
Results: Paper I: In SPLs, EUS-FNB and EUS-FNA had a comparable diagnostic 
accuracy (69 % vs 78%, p=0.31). The combination EUS-FNA+FNB was superior to 
EUS-FNA alone in pancreatic non-adenocarcinoma neoplasms (89% vs 69%, p=0.02). 
Paper II: In SELs, EUS-FNB had a higher accuracy compared with EUS-FNA (83% 
vs 49%, p<0.001) leading to the reduced need for additional diagnostic procedures 
(14% vs 53%, p<0.001). Paper III: The EUS-FNB-tissue was diagnostic for GIST in 
98%, accurate for Ki-67-indexing in 92%, and adequate for successful sequencing in 
98% of the cases. In patients treated with down-sizing imatinib [KIT exon 11 (n=9); 
PDGFRA exon 12 (n=1)], the Ki-67-index was significantly higher in pretreatment 
FNB-tissue compared with resection specimens: Ki-67DIFF = 2.3 (95% CI: 0.67-5.37, 
p=0.005). Paper IV: Pretreatment sequencing, compared with no sequencing, lead to a 
higher rate of accurate down-sizing therapy (97% vs 70 %, p<0.001) and to the 
increased preoperative tumor size reduction on CT scan (32% vs 22%, p=0.036).  
Conclusions: Endosonography-guided fine-needle biopsy sampling has a significant 
diagnostic and clinical value in subepithelial lesions; especially in gastrointestinal 
stromal tumors. The acquired tissue is also accurate for the early tumor proliferation 
rate assessment and genetic profiling of GISTs. This work-up approach facilitates the 
guidance and evaluation of down-sizing tyrosine kinase inhibitor therapy. 
Keywords: endosonography, fine-needle biopsy, pancreatic neoplasms, 
gastrointestinal stromal tumors, KIT, PDGFRA, Ki-67, imatinib, neoadjuvant therapy 
ISBN: 978-91-629-0400-5 (PRINT)   978-91-629-0401-2 (PDF) 
SAMMANFATTNING PÅ SVENSKA 
Bakgrund: Korrekt behandling kräver tillförlitlig diagnos. Via röntgen eller 
endoskopi händer det tämligen ofta att man finner förändringar i 
bukspottkörteln eller förändringar under magtarmkanalens slemhinna där 
diagnosen förblir osäker. Ett vävnadsprov av hög kvalitet krävs då eftersom ett 
brett spektrum av diagnoser är tänkbara, t ex gastrointestinal stromacellstumör 
(GIST). Denna tumörtyp behandlas kirurgiskt men förbehandling med 
målinriktad så kallade tyrosinkinashämmare är inte sällan nödvändig. Sådan 
behandling är effektiv endast vid vissa mutationstyper i onkogenerna KIT och 
PDGFRA. Prognosen vid GIST bestäms även av tumördelningshastigheten. 
Endoskopiskt ultraljud med finnålsaspiration (EUS-FNA) är en värdefull 
diagnostisk teknik för att inhämta cellprov från svåråtkomliga förändringar i 
bröstkorg och bukorgan. EUS-FNA har emellertid svagheter och bristande 
diagnostisk träffsäkerhet. En ny typ av biopsinålar (FNB) för inhämtning av 
sammanhängande vävnad är ett potentiellt bättre alternativ än EUS-FNA. 
EUS-FNB har dock inte utvärderats i prospektiva, jämförande studier.   
Målsättning: Det övergripande syftet med denna avhandling var att studera 
möjligheten att förbättra EUS-baserad diagnostik av förändringar i 
bukspottkörtel och magtarmkanal, särskilt GIST. Ett specifikt syfte var att 
utvärdera EUS-FNB för vävnadsinhämtning och histologisk diagnostik. En 
avslutande strävan var att experimentellt utforska möjligheten att använda 
GIST-vävnad inhämtad via EUS för att redan före start av förbehandling skatta 
tumördelningshastighet och bestämma genetiska profil i enskilda tumörer. 
Metod: På Sahlgrenska sjukhusets endoskopiavdelning inkluderades under 
åren 2012–2015 totalt 68 patienter med pankreasförändringar (delarbete I) och 
70 patienter med förändringar liggande under magtarmkanalens slemhinna 
(delarbete II). Patienterna genomgick rutinmässig cellprovtagning via EUS-
FNA men i tillägg även vävnadsinhämtning med EUS-FNB. Den diagnostiska 
träffsäkerheten jämfördes sedan de två teknikerna emellan. En historisk grupp 
patienter (2006-2011) från samma sjukhus användes också som jämförelse. 
Hos 44 patienter som alla slutligen fick diagnosen GIST (delarbete III) 
färgades den inhämtade vävnaden för markören Ki-67 varpå tumörcellernas 
delningshastighet beräknades. Vävnaden analyserades sedan också med 
gensekvensering av KIT och PDGFRA. I en avslutande studie på GIST-
patienter 2014–2017 (delarbete IV) genomfördes all gensekvensering före start 
av preoperativ förbehandling med tyrosinkinashämmare, t ex imatinib.  
Resultat: Vävnadsinhämtning via den nya provtagningstekniken (EUS-FNB) 
visade sig vara likvärdig med den gängse tekniken (EUS-FNA) vid utredning 
av förändringar i bukspottkörteln. Användandet av bägge teknikerna 
tillsammans ökade dock den diagnostiska träffsäkerheten från 69% till 89% 
vid vissa tumörtyper såsom neuroendokrin pancreastumör (delarbete I).  
Användandet av EUS-FNB var en tydligt bättre metod än EUS-FNA vid 
utredning av förändringar liggande under magtarmkanalens slemhinna. 
Elakartade förändringar diagnosticerades korrekt i 90% av fallen (delarbete 
II). Den höga träffsäkerheten gjorde även att behovet av kompletterande 
utredning efter EUS minskade under åren 2012–2015 jämfört med 2006–2011. 
Tumörvävnad från GIST inhämtad via EUS-FNB var väl lämpad för genanalys 
av KIT och PDGFRA, där mutationsprofilen klargjordes i 43/44 (98%) av 
fallen (delarbete III). Identiska mutationer hittades i operationspreparaten hos 
de 27 fall som sedan opererades. Hos patienter som inte fick förbehandling 
med imatinib stämde tumördelningshastigheten (Ki-67-index) i FNB-vävnad 
väl överens med tumördelningshastigheten i motsvarande operationspreparat. 
Hos förbehandlade patienter var däremot tumördelningshastigheten signifikant 
högre i FNB-vävnad jämfört operationspreparat.  
Omedelbar genanalys av KIT och PDGFRA i FNB-vävnad (delarbete IV) ledde 
till att en högre andel GIST-patienter (97% jämfört 70%) kunde erbjudas 
korrekt förbehandling under åren 2014-2017 jämfört med perioden 2006–
2013. De patienter som fick förbehandling med imatinib under åren 2014–2017 
hade också ett bättre behandlingssvar jämfört motsvarande patienter 2006–
2013. 
Slutsats: Endoskopiskt ultraljud med vävnadsinhämtning via biopsinål är 
diagnostiskt och kliniskt värdefullt vid utredning av förändringar liggande 
under magtarmkanalens slemhinna; i synnerhet då man misstänker 
gastrointestinal stromacellstumör. Vid denna diagnos kan inhämtad vävnad 
även användas för att kartlägga mutationer i GIST-tumören, bedöma dess 
riskprofil och slutligen målinrikta tumörkrympande behandling före kirurgi. 
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1 INTRODUCTION 
“To treat or not to treat?” – that is actually quite often the question in modern 
healthcare. If the answer is “yes”, the obvious next questions would be “whom 
and how to treat?”.  
The intent of this thesis was to elaborate diagnostic methods addressing the 
above questions and by that facilitate the management of patients with 
suspected neoplasms. The improved diagnostics can be one valuable step 
towards what is called personalized medicine1,2.    
1.1 DNA and tumor biology 
Deoxyribonucleic acid (DNA) is the construction code of advanced 
lifeforms3,4. In humans, the DNA molecule is a double helix formation built 
upon nucleotides. Each nucleotide contains a sugar component (deoxyribose), 
a phosphate group, and one of four nitrogen-containing nucleobases - cytosine 
(C), guanine (G), adenine (A) or thymine (T). Two nucleobases of the two 
opposing DNA-strands (base-pairs) are bound together according to the strict 
rule: A-T and C-G.  
Each individual aminoacid, which are the building blocks of proteins, is 
encoded by a triplet of nucleotides, Appendix. The protein-coding fraction of 
the human genome is small (1.5%)5 including some 19 000 genes6. The exons 
are the parts of the genome encoding the actual protein, while the introns are 
the fragments removed at transcription. 
1.1.1 How to unveil the base-pair sequence of DNA and why? 
In numerous malignancies such as breast cancer and lung cancer, the tumor 
biology, the prognosis, and the recommended treatment depend on the DNA-
sequence of certain genes7,8. Luckily enough, elegant methods, i.e. sequencing, 
have been developed to decipher the base-pair sequence hidden within the 
DNA. The Sanger sequencing method, outlined in Figure 1, is still in use after 
initially being elaborated in the nineteen seventies9,10. During the last two 
decades there has been an increased need for fast and large-volume DNA-
sequencing. As a result, more advanced methods have been developed, which 
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are mainly entitled next generation sequencing (NGS). The specific NGS-
method used in this thesis will be further described in chapter Methods.  
 
 
 
Figure 1. Sanger sequencing - the dideoxy chain termination method.  
a) DNA synthesis of the gene of interest by PCR and the addition of regular 
deoxynucleotides (dNTPs) and fluorescently dye-labeled dideoxynucleotides 
(ddNTPs). The ddNTPs lack the 3’ OH-group, which prevents a phosphodiester bond 
with the next dNTP whereupon further synthesis stops (red cross). b) Gene fragments 
of all possible lengths are formed, everyone ending with a fluorescent ddNTP. 
Subsequently, the fragments are separated by capillary electrophoresis, in which the 
shortest fragments move the fastest. At the end of the capillaries a laser beam makes 
the ddNTPs emit fluorochromes of pre-defined wave-lengths which are recorded by a 
detector. c) Finally, an electropherogram of the DNA-sequence can be produced. 
Adapted from Verma et al and reprinted with permission from Springer Nature. 
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1.1.2 Mutations and the formation of neoplasms 
A mutation is defined as an alteration of the normal DNA-sequence in a certain 
gene11. Mutations can be acquired (only found in a specific cell population) or 
inherited (found in all somatic or germ cells)12. There are different types of 
mutations such as point mutations, deletions, and insertions, which all change 
the base-pair sequence13. Consequently, the mutated DNA may lead to an 
altered gene expression and protein product.  
A neoplasm is an abnormal growth of tissue, which often forms a mass or a 
tumor14. Due to a mutation or a chromosomal translocation, a so-called proto-
oncogene can evolve into an oncogene, which is a type of gene that has the 
potential to stimulate the formation of a neoplasm. In general, proto-oncogenes 
are involved in cell-growth and cell differentiation. A famous example of an 
oncogene is the Bcr-Abl gene. The Bcr-Abl gene codes for a permanently active 
tyrosine kinase, which leads to the uncontrolled cell proliferation seen in 
chronic myeloid leukemia15 
The development of a neoplasm is a multi-step process, in which normal cells 
gradually transform into cells with increasing abnormal properties such as 
decreased cell differentiation, increased cell division, and loss of apoptotic 
control. Often, sequential, acquired mutations in multiple genes of the DNA 
contribute to the neoplastic process16.  
A carcinoma is a neoplasm of epithelial origin. It is the most common type of 
malignancy exemplified by lung cancer, breast cancer, and gastric cancer. A 
sarcoma is a neoplasm of mesenchymal origin, i.e. the supporting tissue such 
as bone, cartilage, and connective tissue.  
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1.2 Solid pancreatic and subepithelial lesions 
1.2.1 Solid pancreatic lesions – not only adenocarcinomas 
Neoplasms in the form of solid lesions in the pancreatic parenchyma can be 
detected by radiology either incidentally or in the work-up of symptomatic 
patients. Even by the means of modern cross-sectional imaging and 
transabdominal ultrasound, it can be difficult to firmly diagnose the underlying 
diagnostic entity17,18.  
Among different neoplasms, pancreatic ductal adenocarcinoma (PDAC) is the 
most common one19, while pancreatic neuroendocrine tumors (PNET) and 
metastases have a similar appearance at imaging17. The diagnostics is also 
complicated by the fact that a focal pancreatitis may imitate a neoplasm and 
present as an SPL. Therefore, the sampling of numerous SPLs is warranted for 
the microscopic assessment of the cellular morphology. In addition, the 
reliable diagnosis of neoplasms other than PDAC, requires complementary 
immunostaining for entity-specific tumor markers20-22. Problematically, the 
pancreas is located deep within the abdomen and challenging to reach by a 
transabdominal approach.  
1.2.2 Subepithelial lesions – a wide spectrum of entities 
Subepithelial lesions (SEL) are common incidental findings at routine 
endoscopy 23. A SEL can be defined as ”any intramural growth underneath the 
gastrointestinal mucosa, where the etiology cannot readily be determined by 
diagnostic endoscopy or barium radiography”24. An extramural lesion 
originating from outside the wall may also present as a SEL during 
endoscopy25,26, Figure 2. The expression subepithelial lesion is purely 
descriptive and it provides no information on the diagnostic entity of the 
underlying lesion. Under the SEL-umbrella, there hide lesions ranging from 
highly malignant sarcomas to completely benign duplication cysts27. 
Consequently, and as with SPLs, the sampling of these lesions is more or less 
required. 
Endosonography and pretreatment tumor profiling
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Figure 2. Four subepithelial lesions symbolizing the complexity of diagnostics by 
routine endoscopy. Images by the author. 
A) A schwannoma of the minor curvature of the gastric body. 
B) An extramural structure, in this case the benign gall bladder of a young woman, 
mimicking a true subepithelial tumor in the antral part of the stomach.   
C) A lipoma situated in the second part of the duodenum. 
D) A gastrointestinal stromal tumor originating from the distal part of the gastric body.
  
However, numerous subepithelial lesions are difficult to discriminate from one 
another only by their cellular morphology, which indicates the need for 
immunochemistry25. The expected immunostaining pattern of three common 
SELs is presented in Figure 3. The rational clinical management of SELs 
requires a reliable diagnosis, which unfortunately cannot be obtained by 
routine gastroscopy23,28,29 or by PET-CT30,31. To date, the challenging 
diagnostics of SELs has led to a wide spread surgical approach with the 
resection of these lesions to obtain the diagnosis23. That is not optimal 
management since surgery is associated with morbidity and since entirely 
benign lesions should not be resected. 
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Figure 3. EUS-FNB-tissue histology slides (magnification x 20) of a gastrointestinal 
stromal tumor (A); a schwannoma (B); and a leiomyoma (C). Top row: Routine 
hematoxylin and eosin staining.  Middle row: c-KIT immunostaining (CD117). The 
GIST-tissue is positive (brown color) while the schwannoma and the leiomyoma are 
negative (blue color). Bottom row: The GIST-tissue is negative (blue) for DESMIN 
immunostaining, while the leiomyoma is positive (brown). The schwannoma in the 
middle stains positively for S-100 (brown). Images by the author. 
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1.3 Gastrointestinal stromal tumors (GIST) 
Gastrointestinal stromal tumor is one entity commonly presenting as a 
subepithelial lesion. As described below, a GIST constitutes a most 
challenging and demanding neoplasm both from a diagnostic, prognostic, and 
a therapeutic point of view.   
1.3.1 Epidemiology 
Gastrointestinal stromal tumors (GIST) are exotic in the sense that this 
diagnostic entity did not exist until some twenty years ago. Instead GISTs were 
regarded as smooth-muscle cell neoplasms originating from the stomach and 
incorrectly named gastric leiomyomas32. A true GIST is a neoplastic entity of 
its own. It is hypothesized that it originates from the interstitial cells of Cajal 
(ICC)33, “the gut pacemaker cells”, which are responsible for the initiation of 
the contractile bowel movements 34. 
GIST is a relatively rare tumor, but the most common mesenchymal neoplasm 
of the gastrointestinal tract35. A clinical incidence of approximately 0.8 in 
100.000 has been suggested36 with similar numbers recorded in a large 
Swedish cohort37. Hereditary GISTs may appear at young age in individuals 
with germline mutations12,38, while sporadic GISTs are diagnosed at a median 
patient age of 70 years without a clear sex predominance28,36. GISTs most 
commonly arise from the stomach (~50 %)39,40 or the small bowel (20-30 %), 
but may also originate from the large bowel (<10 %) or rarely the 
retroperitoneum. The clinical presentation of GIST is diverse28 but the incident 
detection during upper GI endoscopy is common37.  
1.3.2 Pathogenesis and molecular pathology 
To a large extent, the pathogenesis of sporadic GISTs can be explained by 
mutually exclusive mutations in any of two proto-oncogenes - KIT and 
PDGFRA41. 
The KIT-gene is located in the long arm (q) of chromosome 4 and includes 21 
exons of 34 kB42. The gene encodes a 145 kDa transmembrane tyrosine kinase 
receptor, TRK (also referred to as c-Kit or CD 117 in immunostaining)43. The 
receptor has an extracellular binding site of the agonist ligand SCF (stem cell 
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factor), Figure 4. The attachment of the SCF-ligand results in receptor 
dimerization, phosphorylation of tyrosines by the intracellular receptor 
domain, and finally activation of subsequent down-stream signaling pathways 
leading to cell proliferation and reduced cell apoptosis44,45. 
The c-Kit-receptor is expressed by the interstitial cells of Cajal, but also by 
hematopoetic cells. In 1993, mutations in KIT were identified as the cause of 
ligand-independent tyrosine kinase activity resulting in mast cell leukemia46.  
Later Hirota and co-workers described such “gain of function-mutations” as 
the key driver of the oncogenesis also in GIST47.  Commonly mutated exons 
of KIT are exon 11 (~75 %), exon 9 (~15 %), exon 13 (~2 %), and exon 17 (~1 
%)48-50. 
The platelet derived growth factor alpha gene (PDGFRA) is also located on 
chromosome 4. It is suggested to have the same ancestral gene as KIT42,51. As 
with KIT-mutations, PDGFRA-mutations leads to a permanently active 
receptor Figure 4. PDGFRA-mutations located in exon 12, 14, or 18 are 
responsible for around 7-10 % of sporadic GISTs and are associated with 
gastric origin and less aggressive progression52,53. 
1.3.3 The histopathology of GISTs 
A spindle-cell morphology is the typical microscopic appearance of GIST. 
However, positive immunostaining for hematopoetic progenitor antigen 
(CD34), c-KIT (CD117), or anoctamin 1 (DOG-1)47,54,55 is required for a 
conclusive diagnosis, Figure 3. Importantly, the positive c-KIT-
immunostaining is not caused by a KIT-mutation per se, which instead 
modifies the function of the c-KIT-receptor. 
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Figure 4. A schematic outline of the c-KIT-receptor. 
A gain-of-function mutation (dots in blue, yellow, and red) leads to the ligand-
independent dimerization and activation of the receptor resulting in 
autophosphorylation of tyrosines and activation of downstream signaling pathways. 
The location of primary, sporadic and primary, hereditary mutations in KIT and 
PDGFRA are indicated by blue and yellow dots respectively. The location of 
secondary mutations induced by TKI-therapy are indicated by red dots. Adapted from 
Lasota et al and reprinted with permission from John Wiley and Sons. 
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1.3.4 Prognostic risk and tumor proliferation rate 
The prognosis of patients with GIST varies from excellent to poor depending 
on the tumor stage at the time of diagnosis56. The prognostic risk is based upon 
a) the tumor size and b) the tumor proliferation rate (mitotic index - MI); with 
both parameters included in the advocated risk score of the NIH (National 
Institutes of Health)57, Appendix. The Ki-67-index is an alternative indicator 
of the tumor proliferation rate used in numerous neoplasms58,59 and the level 
of the Ki-67-index strongly correlates with the prognosis also in GIST37,60-62. 
1.3.5 Treatment 
Small GISTs (<1 cm) can be managed conservatively with watchful waiting, 
especially in elderly patients63. Otherwise, surgery is the primary treatment of 
resectable GISTs and can cure 60 % of the patients as the single therapy56. 
Tumor rupture during surgery significantly increases the risk for recurrence64.  
Tyrosine kinase inhibitors (TKI) and gene-driven targeted therapy 
Imatinib (a 2-phenyl amino pyrimidine derivative) is a drug belonging to the 
family of tyrosine kinase inhibitors (TKIs). It was initially developed to treat 
chronic myeloic leukemia. In 2001, there was a first report on the efficacy of 
imtinib in GIST65. This breakthrough finding has revolutionized the treatment 
of GIST-patients66-68. Side effects related to imatinib therapy are however not 
rare69. Anemia, edema, nausea, diarrhea, and dermatitis are common reasons 
for dose reduction or for discontinuation of therapy68,70. As adjuvant or 
palliative therapy, the standard dose of imatinib is 400 mg daily71. High dose 
therapy (800 mg daily) is recommended for certain molecular subtypes, such 
as KIT exon 9-mutants48,72, but it increases the risk of side-effects. 
Tumor sensitivity to imatinib therapy 
Imatinib therapy is genotype-driven71 meaning that only tumors with certain 
mutations are sensitive to treatment. Almost all KIT exon 11-mutants are 
sensitive to imatinib as are PDGFRA exon 12-mutants73. However, specific 
subtypes of KIT exon 11-mutations such as the L576P-mutant respond poorly 
to imatinib74. Primary resistance or reduced sensitivity to imatinib, is also 
related to mutations in exon 9 or 17 of KIT, to mutations in exon 18 of 
Endosonography and pretreatment tumor profiling
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PDGFRA, or to the wild type profile (WT)48,73,75-77, in which no mutations in 
KIT or PDGFRA are detected. 
There is no indication for therapy in PDGFRA exon 18 D842V-mutants78 and 
no obvious benefit has been found in WT-tumors79. Regarding KIT exon 13-
mutants the knowledge is limited. These tumors are probably not resistant to 
imatinib but the response to therapy does not seem to be as good as in KIT exon 
11-mutants80,81. So-called secondary mutations in KIT (exon 13, 14, 17) and 
PDGFRA can evolve during TKI-therapy leading to drug resistance82. 
Indications for imatinib therapy in GIST 
While the benefits of surgery in metastasizing GIST remains unclear83, 
imatinib given as a palliative treatment has dramatically improved the 5-year 
overall survival which is now approaching 85%19. This number can be 
compared with a median overall survival (OS) limited to 18 months in high-
risk GISTs not available for radical surgery (R0) during the pre-imatinib era37. 
As another comparison, the prognosis of a regular leiomyoma is excellent with 
a very low risk for malignant transformation84. There is also solid support for 
36 months of postoperative adjuvant imatinib therapy in NIH high-risk tumors 
and some support considering intermediate risk tumors72.  
Preoperative imatinib treatment is called neoadjuvant or down-sizing therapy. 
Studies have proved that down-sizing imatinib is safe85,86 and that it facilitates 
the resection of borderline resectable tumors87. There is also growing evidence 
and support for neoadjuvant imatinib in terms of disease free survival (DFS) 
and overall survival87,88. Guidelines recommend neoadjuvant imatinib to 
enable organ preserving, radical surgery72.  
1.3.6 Shortcomings in current GIST diagnostics and therapy 
The complexity of GIST has resulted in severe shortcomings in current work-
up and therapy. The need for sampling and immunostaining has left many 
GIST-patients without a preoperative diagnosis23,89. The prognostic risk has 
been speculative without serious attempts to assess the tumor proliferation rate 
at the preoperative stage. Finally, down-sizing imatinib therapy has been 
initiated purely by chance and not based on the results of mutational analysis85.     
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1.4 Endosonography and tumor sampling 
 
1.4.1 What is ultrasound? 
Sound is mechanical energy appearing in the form of vibrations moving 
through a medium such as a gas or a liquid. The propagation of sound occurs 
when energy displace molecules from their original position and make them 
oscillate along the direction of what is described as the sound wave. The wave 
can be mathematically expressed as: 
c = f·λ 
According to this equation, the wavelength (λ) is proportional to the velocity 
(c) of the wave propagation and inversely proportional to the frequency (f) of 
the molecule oscillations90. The formula above implicates that the wave 
frequency is the number of oscillations (cycles) per unit of time. A frequency 
of 1 cycle per second is expressed as 1 Hertz (Hz). Ultrasound is defined as 
frequencies greater than 20 kHz, i.e. waves inaudible by humans.  
Ultrasound used in medicine normally operates within wave lengths ranging 
from 2–20 MHz91. An ultrasound wave is emitted from the so-called 
transducer, which also receives and analyses the reflected wave.  
According to the equation of velocity, the distance (D) from the transducer to 
the organ or object reflecting the ultrasound wave is: 
D = 𝑐𝑐·𝑡𝑡
2
 
where (c) is the wave velocity and (t) is the recorded time from the emission 
of the wave (speaking) to the return of the wave (listening). 
Consequently, the ultrasound processor will be able to calculate the position of 
all reflecting objects within the examined part of the human body. Finally, all 
recorded echoes are reproduced in a two-dimensional fashion – the ultrasound 
image92. 
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1.4.2 The rise of endosonography (EUS) 
The first ever known outline of an endoscopic procedure was described by 
Hippocrates (460 – 375 B.C)93. It was not until 1881 that the era of flexible 
endoscopy started94. The potential use of ultrasound in medicine was proposed 
in the early 1940’s95. Eventually, transcutaneous ultrasound was implemented 
into multiple areas of medical diagnostics. Nevertheless, the imperfection of 
transcutaneous ultrasound in the diagnosis of pancreatic diseases96 lead to the 
idea that the attachment of an ultrasound transducer onto an endoscope would 
improve the imaging of the pancreas. After intense animal tests in the late 
1970’s the first primitive echoendoscope was launched in 198097. The 
transducer of modern echoendoscopes is often of the type curved linear-array, 
which enables the sonographic visualization of the needle98, Figure 5. 
1.4.3 Endosonography-guided acquisition of tumor material 
Certainly, the assessment of the ultrasound image is an important part of EUS-
diagnostics but it alone cannot unveil the diagnosis in many lesions presenting 
as a SEL99, Figure 6. Therefore, there is a frequent need for lesion sampling.  
EUS-guided fine needle aspiration (EUS-FNA) 
Almost thirty years ago, dr Peter Vilmann and colleagues were pioneers in the 
performance of EUS-guided sampling100,101. Early generation EUS-FNA-
needles were designed for multiple use, Figure 5, while modern needles are 
disposable. In general, the FNA-needles are constructed with a so called “open-
tip” design, Figure 5. In experienced hands, EUS-FNA is a safe procedure 
with a low risk for infection, bleeding, perforation, and pancreatitis102. EUS-
FNA is well aimed for certain types of lesions, such as malignant lymph 
nodes103,104. Rapid on-site cytology evaluation (ROSE) may increase the yield 
of EUS-FNA but the diagnostic benefit is debated105,106. 
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Figure 5. Left: A first generation echoendoscope (Pentax FG 32 UA) with a 2 mm 
working channel. The transducer is of the type curved linear-array, which enables the 
ultrasonographic visualization of the open-tip FNA-needle (with a stylet) which 
protrudes from the working channel and appears below the transducer. Right: The 
first dedicated instrument for the performance of EUS-guided sampling mounted on 
an echoendoscope. The device was developed by the Danish surgeons dr Peter 
Vilmann and dr Soren Hanecke in the early 1990´s (GIP-Medizintechnik/Mediglobe 
GmbH, 1993). Photos reprinted with courtesy of Prof Peter Vilmann. Herlev Hospital. 
 
 
 
Figure 6. The endosonography image is informative but cannot distinguish all 
diagnostic entities from one another. Left (A): A hypoechoic lesion arising from the 
forth wall layer of the gastric fundus. Right (B): A much similar lesion with the same 
echocharacteristics also situated in the gastric fundus. EUS-FNB including diagnostic 
immunostaining revealed that (A) was a benign leiomyoma and (B) was a 
gastrointestinal stromal tumor. The leiomyoma should be left without further 
treatment, while the GIST should be treated with surgical resection if possible. Images 
by the author. 
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1.4.4 Unmet needs in EUS-FNA 
However, EUS-FNA is imperfect. Performed in solid pancreatic lesions, EUS-
FNA has only a moderate sensitivity for malignancy (~85 %) according to a 
large meta-analysis107. Moreover, the vast majority of publications have 
included mostly ductal adeocarcinomas while few studies have addressed other 
entities such as neuroendocrine tumors and metastases105,108. In the case of 
subepithelial lesions, EUS-FNA performs even worse with a low diagnostic 
accuracy leaving as much as every second patient without a diagnosis109,110. 
Lesions measuring < 2 cm is even more demanding111. 
In GIST, the preoperative diagnostics by EUS-FNA is difficult as such. The 
treating clinician is also burdened by the fact that a correct diagnosis is not 
enough. Preoperative information on the tumor proliferation rate and the 
genetic profile of KIT and PDGFRA is a must to offer patients a personalized 
care at an early stage.   
Big effort has been invested in improving the accuracy of EUS-FNA. The use 
of suction during sampling is beneficial112. Unfortunately, most trials 
addressing other measures have been discouraging. The use of a 22 gauge 
needle, which is somewhat larger compared with the standard 25 gauge needle, 
is futile113,114. A number of FNA-passes beyond four is of no use115,116. Two 
passes is often sufficient if ROSE if performed116.   Sampling with the use of a 
stylet117 or by the use of slow stylet retraction (“slow-pull”)118 does not 
improve the yield of EUS-FNA. Obviously, there is a great need for alternative 
approaches. 
1.4.5 EUS-guided fine needle biopsy sampling (EUS-FNB) 
Due to the drawbacks of EUS-FNA there has been no lack of attempts to 
acquire whole tissue by EUS for the processing of histology specimens. 
Unfortunately, the first generation of EUS-needles aimed for histology (EUS-
TCB) showed disappointing results with a high frequency of technical 
failures109, low yield, and non-superior diagnostic accuracy compared with 
EUS-FNA119. Problematically, the lack of appropriate samples has also 
disabled the performance of preoperative Ki-67-indexing and DNA-
sequencing of GIST. 
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In recent years a new generation of biopsy needles (EUS-FNB) has been 
developed. The tip-design differs somewhat in between these needles 120-122 but 
they are all, such as the side-fenestrated, reverse bevel FNB-needle121, aimed 
for the acquisition of whole tissue.  
Whether or not the use of the new FNB-needles and the processing of histology 
specimens can improve the diagnostics of SPL and SEL is not known. 
Prospective studies are lacking. Moreover, the patient safety of EUS-FNB has 
not been properly evaluated. Is there any clinical benefit motivating a shift 
from EUS-FNA? Finally, and maybe most worrying, there is a complete lack 
of studies addressing the important issue of pretreatment characterization of 
GISTs. Potentially, tissue acquired by EUS-FNB could be the valuable source 
for this information. 
 
1.5 The research field in summary 
In summary, despite modern diagnostic equipment the physicians and the 
surgeons of today still face numerous pancreatic and subepithelial lesions with 
unknown malignant potential and unclear prognosis. Concerning 
gastrointestinal stromal tumors, the preoperative lack of information on the 
tumor genetics and the tumor proliferation rate is equally problematic in the 
clinical context.  
At present, and due to the lack of a definitive diagnosis, the clinical 
management of the above lesions is commonly erroneous with a substantial 
risk of maltreatment. In benign lesions, there is a high risk of unwarranted 
resection leading to patient morbidity. In malignant lesions, there is a risk of 
delayed, targeted therapy. The pretreatment acquisition of appropriate tumor 
material and the extensive analyses of this material would be a crucial step 
towards true personalized medicine.  
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2 AIMS 
The global aim of the studies included in this thesis was to investigate a biopsy 
approach in EUS-guided sampling procedures with respect to the patient safety 
and the diagnostic accuracy. The focus was the sampling procedures 
performed in suspected neoplasms presenting as solid pancreatic lesions or as 
subepithelial lesions.  
A complementary aim was to evaluate the clinical impact of using the biopsy 
approach as compared with routine EUS-guided fine-needle aspiration.  
A final aim was to explore the feasibility and clinical importance of 
pretreatment genetic profiling and tumor risk assessment of gastrointestinal 
stromal tumors by the use of tissue acquired by EUS-guided sampling. 
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3 PATIENTS AND METHODS 
The research presented in this thesis was performed using a deductive, 
empirical approach and a quantitative methodology meaning that first the study 
hypotheses were formulated and then they were tested by the measurement of 
different variables.  
There are two main types of study design. In the observational study, the 
course of events within the study population is (presumably) not affected by 
the conduction of the study123,124. The observational study enables the 
researcher to identify associations, but not necessarily causality, in between 
the study variables. As an example, overweight has been found to be associated 
with an accelerated regional bowel transit125. Whether or not overweight was 
the cause of the detected fast transit remains however unclear (it could be vice 
versa).     
The current thesis is based on interventional studies124, which have the aim to 
draw conclusions on causality, i.e. if the study intervention (the independent 
variable) results in a detectable difference in the study outcome (the dependent 
variable). As an example, bowel cleansing with sodium picosulfate, as 
compared with polyethylene glycol, was found to result in less patient 
discomfort126. Some property of the cleansing fluid was the probable cause of 
the improved patient tolerance.  
3.1 Study design and patient selection 
The Sahlgrenska University Hospital (SU) is the tertiary center in the western 
part of Sweden (Västra Götaland and Halland) for patients with pancreatic 
malignancies, neuroendocrine neoplasms, sarcomas, and gastrointestinal 
stromal tumors. From centers within this region, a vast majority of new cases 
with such a suspected diagnosis is referred to SU for diagnostic work-up and 
care. The GEA endoscopy unit of SU (SU-GEA) is the tertiary 
endosonography center of the region performing all but few of the EUS-
examinations in these patients.  
The study characteristics of the four papers included in this thesis are presented 
in Table 1. 
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Table 1 Study characteristics of the four papers  
 Paper I Paper II Paper III Paper IV 
Design Prospective, 
interventional 
Prospective, 
interventional 
Prospective, 
exploratory 
Prospective, 
interventional 
Population SPL SEL GIST GIST 
Patients (n) 68 70 44 59 
Study aim Improve 
diagnostics 
Improve 
diagnostics 
Explore new 
method 
Implement new 
method 
Intervention EUS-FNB EUS-FNB (EUS-FNB) Pretreatment 
sequencing 
Comparison EUS-FNA EUS-FNA (EUS-FNA) Posttreatment 
sequencing 
Ref cohort  2006-2011 2006-2011 2006-2011 2006-2013 
Outcome(s)     
Primary Diagnostic 
accuracy 
Diagnostic 
accuracy 
Diagnostic 
accuracy 
Therapy 
adequacy 
Secondary Adverse events 
 
Adverse events 
Clinical impact 
Sample 
adequacy for 
Ki-67 and MA 
Tumor 
response 
*) MA=mutational analysis 
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Paper I-III 
During 2006–2011, all patients subjected to EUS-guided sampling at SU-GEA 
were included in a EUS-quality research project with the intent to evaluate the 
performance of EUS-FNA (or EUS-TCB in few cases). This cohort was the 
base-line cohort, Figure 7. These patients were part prospectively (2009–
2011), part retrospectively (2006–2008) included.  
In 2011, and due to the drawbacks of EUS-FNA, we designed a single-center, 
prospective, interventional study on the diagnostic accuracy of reverse-bevel 
EUS-FNB amongst all in solid pancreatic lesions and subepithelial lesions 
including GISTs. The study was registered in the ClinicalTrials.gov database 
(NCT02360839). 
The interventional study was launched in 2012 and continued until the end of 
2015. This time frame was the study cohort. Patient recruitment and inclusion 
of the study cohort was exclusively performed at the SU-GEA. The patients 
were identified at referral and enrolled consecutively as study subjects by one 
of the endosonographers (RS/PH). 
During a short pilot phase in the beginning of 2012, the new reverse bevel 
FNB-needle was tested by the endosonographers in some single needle EUS-
FNB procedures (SPL: n=6; SEL: n=10). The specific inclusion and exclusion 
criteria (Paper I-II) are presented in Figure 8. Regarding Paper III, only lesions 
with a final diagnosis of GIST were included for further analyses.  
The patients included in Paper I were not included in any of the other papers. 
Some patients included in Paper II were also included in Paper III. Some 
patients included in Paper III were also included in Paper IV. 
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Figure 7. A timeline of the different study periods (Paper I-IV). Boxes in green 
symbolize the two main study cohorts, while the boxes in blue symbolize the historical 
cohort of patients of the same center used for reference and comparison.   
 
 
 
Figure 8. A flow-chart of the enrollment process (Paper I-II). Exclusion criteria in 
dark grey boxes. The study pilot phase within the dashed lines.   
 
 22 
Paper IV 
Exploratory DNA-sequencing of GISTs by the use of FNB-tissue was initially 
performed (Paper III). Encouraged by the positive results, we decided in 2014 
to initiate a single-center, prospective, interventional study investigating 
immediate, pretreatment sequencing of FNB-tissue as a routine analysis in the 
work-up of GIST-patients with a need for down-sizing imatinib therapy. 
Eligible study subjects for prospective inclusion (2006–2017) were the patients 
with a highly suspicious GIST, who were referred to SU and evaluated for 
down-sizing imatinib therapy. The patients considered appropriate for up-front 
surgical resection or for watchful waiting were excluded as were patients in 
whom GIST was never confirmed by histopathology. Patient recruitment was 
performed at the SU-GEA or in some cases at the Surgery Department 
outpatient Unit by the study surgeon (BN)37. 
During 2006–2013 (the reference cohort, RC) no pretreatment sequencing of 
preoperative GIST-tissue or cells was performed, Figure 7. Sequencing was 
instead performed on surgical specimens or on EUS-samples late after the 
procedure.  
During 2014–2017 (the immediate sequencing cohort, ISC) all eligible patients 
were subjected to high-priority, pretreatment EUS-FNB with immediate 
sequencing (<2 weeks) of the acquired tumor material, Figure 7. Single-needle 
EUS-FNB was performed after January 2016. In the few cases already 
diagnosed at the time of referral, i.e. by endoscopy forceps or transabdominal 
ultrasound-needle biopsy (TUS-NB), no EUS was performed but instead the 
obtained tumor material was used for sequencing.  
3.2 Ethical considerations 
This research project, including all the papers here presented, was reviewed 
and approved by the Regional Ethical Review Board of Gothenburg (REPN, 
Project ID: 573-09 and 1092-11).  
In accordance with the Helsinki Declaration127 written, informed consent was 
obtained from all study patients enrolled prospectively.  
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3.3 Specific methodological considerations 
3.3.1 Endosonography and EUS-guided sampling 
After written, informed consent, all the patients fulfilling the inclusion criteria 
were examined by EUS as further specified in Paper I/II. Except for the pilot 
phase cases, the sampling of all lesions was performed with both EUS-FNA 
for cytology (Paper I: a 25 gauge needle; Paper II/III: a 22 gauge or a 25 gauge 
needle) and with reverse bevel EUS-FNB for histology (Paper I: a 22 gauge 
needle; Paper II/III: a 19 gauge or a 22 gauge needle). A photo of the needle 
tips is shown in Paper II (Figure 1). 
By blocks of four and by using sealed envelopes the patients were randomized 
to first pass with FNA or FNB. The second pass was performed with the other 
needle. Further passes were performed by alternating the needles. A technical 
failure was defined as the non-ability to target the lesion. In both EUS-FNA 
and EUS-FNB, the needle tip was placed, if possible, in a non-necrotic part of 
the lesions. During 5–15 seconds and with suction applied (10 ml), the needles 
were moved 8-10 times to and fro in different directions during each pass, i.e. 
“fanning”128, Figure 9. The suction was increased (20 ml) if poor initial yield. 
Rapid on-site evaluation (ROSE) was performed when the cytotechnician was 
available. The samples were then handled as further described in Paper I/II.  
 
 
Figure 9. Endosonography-guided fine-needle aspiration of a hypoechoic, intensely 
vascularized pancreatic neuroendocrine tumor. The EUS-needle presents as a thin 
white line and appears from the left in the upper part of the tumor. Image by dr Sadik.  
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3.3.2 Cytology, pathology, and immunohistochemistry 
 
The FNA-samples were directed to the study cytopathologist (AD) and the 
FNB-samples to the study pathologist (ON). After the preliminary diagnosis 
based on the cellular morphology (hematoxylin-eosin-staining), 
immunostaining was performed using entity-specific monoclonal antibodies as 
outlined in Paper I-III. 
3.3.3. The assessment and classification of samples 
Based on the cytomorphology, the FNA-samples and the FNB-samples were 
assessed as representative or non-representative. The non-representative 
samples, being defined as acellular aspirates or biopsy specimens, 
contaminated epithelium only, or obscuring artifacts, were per definition 
categorized as non-diagnostic. Only the samples containing adequate cells or 
whole tissue of the target lesion were regarded representative. Based on the 
cellular morphology and the immunostaining pattern, the representative 
samples were then further categorized as diagnostic or non-diagnostic 
according to the details and prerequisites in Paper I-III.  
 
3.3.4 Follow-up, retrieval of clinical data, and reference standard 
The study subjects were monitored post-EUS by visits to the outpatient unit of 
the Sahlgrenska University Hospital, which was responsible for the decision 
on surgical resection and on tyrosine kinase inhibitor therapy (GIST). The 
medical files of all cases were carefully reviewed post-EUS at least until the 
final diagnosis was established or until patient death. The diagnostic work-up 
before and after the EUS was recorded. In patients subjected to surgery, the 
pathology report of the resected specimen was used as the reference standard. 
In not resected cases, a conclusive (cyto)pathology report of the EUS-sampling 
itself or of an alternative sampling modality was accepted. If a tissue-based 
final diagnosis was not obtained, the clinical diagnosis at a minimum of 12 
months follow-up was used.  
 
The Standards for Reporting of Diagnostic Accuracy (STARD) protocol129-131 
was applied during the conduct of the research project.  
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3.3.5 Analysis approach 
Two different approaches can be applied in the evaluation of diagnostic tests. 
In the per-protocol analysis only the evaluable cases count132. This implicates 
that only technically successful procedures and procedures with an adequate 
yield are included in the analysis. In the intention-to-diagnose analysis all 
cases count133. In the context of an EUS-sampling study, this means that both 
technical failure procedures and procedures with an inadequate or non-
representative yield are included in the analysis. The intention-to-diagnose 
approach will in most scenarios lead to a lower diagnostic accuracy as 
compared with the per-protocol analysis134. Meanwhile, it provides a more 
realistic picture of the intrinsic potential and clinical utility of various 
diagnostic tests133. 
Repeated procedures should not be included in the calculation of the diagnostic 
accuracy since such a generous approach inevitably leads to the risk of 
overestimating the utility of a certain diagnostic test. In this thesis, a 
conservative approach was applied by using the intention-to-diagnose analysis 
and by including only the index-sampling procedures.  
3.3.6 Patient safety (Paper I-III) 
The medical files of the study subjects were carefully reviewed post-EUS to 
detect any adverse post-EUS. Via the digital system of the institution, any visit 
to a Swedish hospital can be detected. In addition, the referring institution was 
requested to report any adverse event. An adverse event was defined as a 
complication within 30 days (such as pancreatitis, infection, or bleeding), 
which resulted in patient contact with or patient care by any hospital 
department.  
3.3.7 Measurement of the clinical impact of EUS-FNB (Paper II) 
To analyze the clinical impact of EUS-FNB (2012–2015) we used as 
comparison the base-line cohort (2006–2011), Figure 7, during which routine 
EUS-FNA (or EUS-TCB in few cases) was performed. In the base-line cohort 
and the study cohort respectively, any additional, diagnostic procedure 
performed after a non-diagnostic EUS and any unwarranted surgical resection 
of the targeted lesions was recorded. A surgical resection was defined as 
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unwarranted if the subsequent pathology report demonstrated a diagnosis that 
should have been managed conservatively.  
3.3.8 Sequencing of KIT and PDGFRA (Paper III & IV) 
All the FNB-biopsies of the GISTs included in Paper III and Paper IV (2012–
2017) were subjected to tumor DNA-sequencing of KIT and PDGFRA. 
Initially (2012–2013) the sequencing was performed on a research basis only 
and late after the date of the EUS. Later (2014–2017), the sequencing was 
performed immediately after the date of the EUS (<two weeks). In the cases 
not subjected to EUS (Paper IV), the pretreatment sequencing was instead 
performed on tissue acquired by transabdominal ultrasound (TUS-NB) or 
gastroscopy-forceps. 
Two different methods for sequencing were applied. In 2012–2015, Sanger 
sequencing, Figure 2, was the method used as thoroughly described in Paper 
III. In 2016–2017, Next Generation Sequencing (NGS) was the method used 
as described in Paper IV and outlined in Figure 10.  
All the corresponding resected specimens of the resected subjects included in 
Paper III were also subjected to sequencing. The mutations detected in the 
FNB-tissue were compared with the mutations detected in the corresponding 
surgical specimens in a case-by-case basis (Paper III). Based on the individual 
mutation profile and in accordance with the available literature of the field, 
each GIST-case was categorized concerning the sensitivity for imatinib (Table 
1 in Paper IV).  
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Figure 10. Next generation sequencing by the Ion torrent technique (Life 
Technologies). After barcoding of DNA and emulsion PCR, the amplified tumor DNA-
fragments are loaded on a semiconductor chip containing thousands of microwells. 
These wells are then flooded with DNA polymerase and the different dNTPs in a step-
wise and repeated manner. With, and only with, the incorporation of a complementary 
base, a proton is released, which leads to the change in the pH of the micro-
environment (far right) detected by an ion-sensitive transistor. Base by base, the 
sequence of the incorporated bases can then be deciphered. Adapted from Verma et al 
and reprinted with permission from Springer Nature. 
 
3.3.9 Measurement of the Ki-67-index (Paper III & IV)  
The pretreatment EUS-FNA-aspirates (Paper III only), the EUS-FNB-tissue, 
and the corresponding surgical specimens of all GISTs were subjected to 
immunostaining of the proliferation marker Ki-67. First, the tumor cell count 
was categorized as adequate or non-adequate for the evaluation of the Ki-67-
index by the study cytopathologist (AD) and pathologist (ON).  
Second, manual counting of the Ki-67-index was carried out both in the FNB-
tissue (Ki-67EUS) and in the corresponding surgical specimens (Ki-67SURG) as 
further described in Paper III. Finally, a case-wise comparison of the Ki-67EUS 
and the corresponding Ki-67SURG was performed. 
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3.3.10 Tumor response to down-sizing imatinib (Paper IV) 
In both cohorts (ISC: 2014–2017; RC: 2006–2013), the evaluation and the 
measurement of the tumor response to down-sizing imatinib therapy was 
performed in the patients receiving standard dose therapy (400 mg daily). The 
evaluation was performed by the use of CT scan, 18FDG-PET, and Ki-67-
indexing (as above). The first two methods were performed twice at the 
preoperative stage; both before (base-line exam) and after (evaluation exam) 
the initiation of down-sizing imatinib. In CT scan, and in line with the 
RECIST-criteria, a positive tumor response was defined as a tumor size 
reduction of at least 30 % (partial response)135.  In 18FDG-PET, a positive 
tumor response was defined as a complete or a partial signal reduction, while 
a signal with no reduction was considered a negative tumor response136. The 
Ki-67-index reduction was measured by comparing the pretreatment sample 
with the resection specimen. 
3.3.11 Outcomes 
The study outcomes in each of the papers are specified in Table1 and in each 
of the papers (Paper I-IV). 
3.4 Statistical considerations 
3.4.1 Sample size calculations and study hypotheses 
To prove or falsify the pre-study, suggested hypothesis one has to estimate the 
number of cases needed in the study. Three factors have to be taken into 
account and included in the sample size calculation:  
1) A study including a small number of cases (observations) has the obvious 
risk of not detecting an actually existing difference between the compared 
groups. This error is called a type II-error (beta). In the papers of this thesis, 
the statistical power (1 – beta) was set at 0.8, i.e. there was an 80 % probability 
of detecting an actually existing difference. 
2) The opposite error, i.e. the detection of a difference between groups not 
actually existing, is called a type I-error (alpha). In accordance with common 
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practice, the alpha-value was set at 0.05, i.e. there was a 5 %-risk of detecting 
a non-existing difference. 
3) The third factor is the minimum difference between groups, which the 
researcher aims to detect. In the papers of this thesis the minimum detectable 
difference was determined based on historical data of our center.   
The null hypothesis of Paper I, II, and III was that the diagnostic accuracy of 
EUS-FNB was equal to routine EUS-FNA. A sample size calculation based on 
this hypothesis and for the comparison of two paired proportions (Mc Nemar’s 
test) was performed including the above three factors137 and by using a web-
based calculator (http://powerandsamplesize.com/Calculators). The following 
number of study cases required was returned: n=66 (Paper I), n=59 (Paper II), 
and n=33 (Paper III). Regarding Paper IV, a sample size calculation was 
performed likewise but for the comparison of two unpaired proportions138. The 
null hypothesis was that down-sizing therapy of GISTs guided by pretreatment 
sequencing is equally often correct as down-sizing therapy initiated by chance. 
By knowing the results and the fixed number of patients included in the 
reference cohort (RC), the sample size required in the immediate sequencing 
cohort (ISC) could be calculated. A number of 59 cases required (ISC) was 
returned. 
3.4.2 The presentation of data and statistical tests 
Descriptive, base-line data were mainly expressed as the median and the range 
or as the in-variable distribution in numbers and percentages (categorical 
variables).  
Before choosing the appropriate statistical tests for the comparison of different 
study variables, an initial analysis of the data distribution and the independence 
of data was performed. Then, the appropriate parametric tests were applied for 
the continuous variables with a sufficient number of observations and with a 
normal distribution of data. Regarding the categorical variables (and 
continuous variables with few observations or with a skewed distribution) the 
appropriate non-parametric tests were used. Independent groups were 
compared using tests for unpaired data whereas dependent groups were 
compared using tests for paired data.  
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An overview of the statistical tests used in the different papers of this thesis is 
presented in Table 2. Details on when the different tests were applied are found 
in the respective paper (Paper I-IV).  
The 95% confidence interval (95% CI) was calculated and presented when the 
number of observations was sufficient, since that, compared with plain p-
values, gives a better perception of the reliability of a certain finding139.  
All statistical calculations were performed using the software SPSS Statistics 
for Windows (version 22.0, IBM Corp., Chicago, IL, USA). All tests were two-
tailed and conducted at a statistical significance level of p<0.05.  
 
Table 2 Tests used for the statistical calculations 
 Paper I Paper II Paper III Paper IV 
Parametric tests     
Student’s t-test  x  x 
Non-parametric tests     
Mann-Whitney U-test 
(unpaired data) 
x x x x 
Fisher’s exact test 
(unpaired data) 
x x x x 
Mc Nemar’s test   
(paired data) 
x x x  
Wilcoxon sign rank test 
(paired data) 
  x  
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4 RESULTS 
4.1 The diagnostic accuracy of EUS-FNB (Paper I-III) 
4.1.1 Sampling of solid pancreatic lesions (Paper I) 
A total of 68 study patients (m/f: 32/36; median age: 67) with SPLs were 
subjected to dual needle sampling EUS-FNA and EUS-FNB. EUS-FNB had a 
similar overall diagnostic accuracy and sensitivity for malignancy compared 
with EUS-FNA, Figure 11. The combined modality EUS-FNA+FNB had a 
higher sensitivity for malignant entities other than PDAC, but was not 
significantly superior to single EUS-FNA in PDACs. There was no technical 
failures recorded neither using EUS-FNB nor EUS-FNA. 
 
Figure 11. The diagnostic outcomes (%) of sampling of SPLs (n=68). EUS-FNA (bars 
in light grey), EUS-FNB (white), and the combined modality EUS-FNA+FNB (dark 
grey). The error bars equal the 95% CI. The diagnostic sensitivity for ductal 
adenocarcinoma (PC) is represented by bars second to the far left, for non-PC tumors 
in the center, and for the whole group of neoplasms by bars second to the far right. 
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4.1.2 Sampling of subepithelial lesions (Paper II) 
A total of 70 study patients (m/f: 34/36; median age: 68) with SELs were 
subjected to dual needle sampling EUS-FNA and EUS-FNB, Figure 12. EUS-
FNB had a significantly higher overall diagnostic accuracy and sensitivity 
compared with EUS-FNA, Figure 13. EUS-FNA was non-diagnostic in all the 
lesions (n=12) in which EUS-FNB was not conclusive for the diagnosis.  
There was one technical failure recorded regarding EUS-FNB. In one patient 
with a 50 mm duodenal tumor the 22 gauge FNB-needle was not possible to 
place in adequate position (failure rate: 1/86, 1.2%). There was no technical 
failure of EUS-FNA. 
 
 
 
Figure 12. The spectrum (n) of diagnostic entities presenting as subepithelial lesions 
in Paper II. ECL-carcinoids = Enterochromaffin-like cell carcinoids. SCLC=Small 
cell lung cancer. MPNST=Malignant peripheral nerve sheet tumor.  
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Figure 13. The diagnostic outcomes (%) of sampling of subepithelial lesions (n=70). 
EUS-FNA (bars in white) and EUS-FNB (bars in grey). The error bars equal the 95% 
CI. The diagnostic sensitivity for benign neoplasms is represented by bars second to 
the far left, for malignant neoplasms by bars in the center, and for the whole group of 
neoplasms by bars second to the far right. 
 
4.1.3 Sampling of GISTs (Paper III) 
A total of 44 study patients (m/f: 19/25; median age: 68) with GISTs were 
subjected to dual needle sampling EUS-FNA+EUS-FNB (n=38) or single 
needle EUS-FNB (n=6). EUS-FNB had a diagnostic sensitivity for GIST of 
43/44 (98 %) and was superior to EUS-FNA in dual needle sampling 
procedures 37/38 (97%) vs 22/38 (58%), p<0.001. The diagnostic sensitivity 
of EUS-FNB was also superior compared with the sensitivity of EUS-FNA 
performed in the baseline cohort 2006–2011, 43/44 (98%) vs 8/16 (50%),      
p<0.001. There was no technical failure recorded neither using EUS-FNB nor 
EUS-FNA. 
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4.2 The patient safety of EUS-FNB (Paper I-III) 
The performance of reverse bevel EUS-FNB was found to be safe and 
associated with few adverse events both in solid pancreatic lesions and in 
subepithelial lesions.  
Regarding SPLs, there was one recorded event among a total of 74 EUS-FNB-
procedures performed (adverse event rate: 1.4%). A 67-year-old man 
developed a necrotizing pancreatitis after transduodenal, single-needle EUS-
FNB of a lesion located in the periampullary region. The procedure was 
performed during the pilot phase of the study. The patient stayed for 4.5 
months in hospital. This incident motivated the exclusion of ampullary lesions 
from study inclusion. 
Regarding SELs, there was one recorded event among a total of 86 EUS-FNB-
procedures performed (adverse event rate: 1.2%). A 68-year old man had a 
post-FNB bleeding in a highly vascularized, 30 mm gastric GIST. As a result 
the patient developed melena the night after the procedure with need for 
erythrocyte transfusion. The bleeding was stopped the day after by gastroscopy 
and local injection of epinephrine.  
As a complimentary finding, the intense dual needle sampling approach 
(FNA+FNB) during the study cohort was not associated with an increase of 
the adverse event rate as compared with the single needle EUS-FNA-
procedures of the base-line cohort [SPL: 0/68 (0%) vs 0/102 (0%), p=1.0; SEL: 
1/70 (1.4%) vs 0/59 (0%), p=1.0]. 
4.3 The clinical impact of EUS-FNB (Paper II) 
EUS-FNB performed in the study cohort of subepithelial lesions (2012–2015) 
resulted in the reduced performance of an additional diagnostic procedure 
compared with the base-line cohort (2006–2011), Table 3. There were also 
fewer unwarranted resections performed in the study cohort compared with the 
base-line cohort, 3/48 (6%) vs 12/35 (34%), p=0.001. 
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Table 3 Additional procedures post-EUS of subepithelial lesions 
 
Study cohort Base-line cohort p-value 
Diagnostic procedures post-EUS    
All lesions (n) 83 73  
No additional diagnostic procedure, n (%) 71 (86) 34 (47)  
Additional diagnostic procedure, n (%) 12 (14) 39 (53)  <0.001 
Diagnostic surgical resection or biopsy 5 19  
Repeated EUS 3 13  
Repeated EUS and diagnostic resection - 3  
PET-CT - 2  
Transabdominal sampling 1 1  
Diagnostic endoscopic EMRa 1 1  
Broncoscopy 1 -  
Repeated endoscopy forceps biopsy 1 -  
    
Malignant lesions (n) 63 38  
No additional diagnostic procedure, n (%) 57 (90) 21 (55)  
Additional diagnostic procedure, n (%) 6 (10) 17 (45) <0.001 
Diagnostic surgical resection or biopsy 2 9  
Repeated EUS 2 4  
Repeated EUS and diagnostic resection - 1  
PET-CT - 2  
Transabdominal sampling 1 1  
Diagnostic endoscopic EMR - -  
Broncoscopy - -  
Repeated endoscopy forceps biopsy 1 -  
a)  EMR=endoscopic mucosal resection 
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4.4 The sequencing in FNB-tissue of GIST (Paper III) 
The FNB-tissue acquired from the 44 GIST-patients in Paper III was adequate 
for successful Sanger sequencing of KIT and PDGFRA in 43/44 (98%) of the 
cases, Figure 14 and Table 3 in Paper III. Among the resected patients (n=27), 
there was full congruence (100%) comparing the mutations detected in the 
FNB-tissue and the mutations detected in the corresponding resection 
specimens. No secondary mutations in KIT or PDGFRA were detected in the 
resection specimens.  
 
 
Figure 14. The spectrum (n) of mutated genes and exons (KIT and PDGFRA) detected 
in the EUS-FNB-tissue of the GISTs included in Paper III (n=44).  
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4.5 The Ki-67-index in FNB-tissue of GIST (Paper III) 
In the patients subjected to dual needle sampling (n=38), the EUS-FNB-tissue 
was more often adequate for the evaluation of the Ki-67-index compared with 
the EUS-FNA-aspirate (35/38, 92%, vs 15/38, 40%, p<0.001). The Ki-67-
index of the FNB-tissue could be calculated in all cases subjected to surgical 
resection 27/27 (100%).  
In the patients subjected to up-front surgical resection without down-sizing 
imatinib (n=12), the Ki-67EUS did not significantly differ from the Ki-67SURG: 
Ki-67DIFF = -0.30 (95% CI: -0.62 to 0.57, p=0.64), Figure 15. There was no 
significant reduction of the Ki-67-index [median Ki-67RED= 10.7% (95% CI: -
22.3% to 26.5%, p=0.70)]. 
 
 
Figure 15. The Ki-67-index (%) assessed in the EUS-FNB-tissue and in the 
corresponding surgical specimen in each of the patients (n=12) who underwent 
resection without preceding down-sizing imatinib therapy (Paper III).  
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4.6 The evaluation of down-sizing imatinib efficacy by 
the Ki-67-index reduction (Paper III) 
Fifteen patients were resected and treated with preoperative down-sizing 
imatinib. In the patients carrying mutations indicating imatinib sensitivity 
[n=10: KIT exon 11 (n=9); PDGFRA exon 12 (n=1)], the tumor proliferation 
rate was found significantly higher in the pretreatment FNB-tissue compared 
with the corresponding resection specimen: Ki-67DIFF = 2.3 (95% CI: 0.67 to 
5.37, p=0.005), Figure 16. There was also a significant reduction of the Ki-
67-index:  Ki-67RED = -91.5% (95% CI: -82.4% to -96.0%, p=0.005). The 
resected tumors carrying mutations suggestive of primary resistance (n=5) 
showed no obvious difference in the Ki-67-index, Paper III. 
 
Figure 16. The Ki-67-index (%) assessed in the EUS-FNB-tissue and in the 
corresponding surgical specimen in each of the patients (n=10) who underwent 
resection after down-sizing imatinib therapy. In all ten tumors a mutation was detected 
indicating full sensitivity to imatinib [KIT exon 11 (n=9); PDGFRA exon 12 (n=1)]. 
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4.7 Guiding down-sizing therapy by pretreatment 
sequencing of GIST-tissue (Paper IV) 
Immediate, pretreatment sequencing of GIST-tissue (EUS-FNB n=46; TUS-
NB n=7; Forceps n=6) was successfully carried out in 57/59 (97%) patients of 
the study cohort (ISC: 2014–2017). Consequently, the number of patients 
receiving a correct down-sizing regimen was significantly higher in this cohort 
(ISC) compared with the reference cohort (RC: 2006–2013), 57/59 (97%) vs 
33/47 (70%), p<0.001, Table 4. 
 Correct Ther Incorrect Ther P-value 
ISC 57 2 <0.001 
RC 33 14  
     
 Standard 
IMA a 
High 
IMA 
Alternative 
TKI b 
No TKI 
therapy 
ISC     
KIT exon 11c 40   1 
KIT exon 13 (p.K642E) 1  1  
PDGFRA exon 12 2    
KIT exon 9 1 1   
Wild type   2 2 
KIT exon 11 (p.L576P)    1 
KIT exon 17 (p.Y823D)    1 
PDGFRA exon 18 (p.D842V)    6 
RC     
KIT exon 11c 31    
KIT exon 13 (p.K642E) 2    
PDGFRA exon 12 -    
KIT exon 9 2    
Wild type 3    
KIT exon 11 (p.L576P) 2    
KIT exon 17 (p.Y823D) -    
PDGFRA exon 18 (p.D842V) 7    
Table 4. bold text = case given incorrect therapy or incorrectly abstained from therapy; white 
background= mutations indication full sensitivity to imatinib; grey background= mutations 
indication reduced sensitivity or resistance to imatinib; standard: 400 mg; high: 800 mg; a) IMA 
= imatinib; b) TKI = tyrosine kinase inhibitor; c) all mutations in KIT exon 11 except p.L576P 
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4.8 Pretreatment sequencing and tumor response 
induced by down-sizing  
Down-sizing standard dose imatinib was initiated in 92 patients (ISC: n=45; 
RC: n=47). In the evaluation by CT-scan (ISC: n=29; RC: n=36), a positive 
tumor response on CT-scan was more common among the ISC-tumors 
compared with the RC-tumors, 19/29 (66%) vs 14/36 (39%), p=0.046. The 
ISC-tumors had also a higher level of tumor size reduction on CT-scan and a 
higher level of Ki-67-index reduction, Figure 17. 
         
Figure 17. Two bar charts demonstrating the tumor response induced by down-sizing, 
standard dose imatinib in patients of the interventional, study cohort (ISC: grey bars, 
2014-2017) and the historical reference cohort (RC: white bars, 2006-2013). Left: The 
bars represent the tumor size reduction (%) comparing the pretreatment, base-line CT 
scan with the evaluation CT scan. Right: The bars represent the Ki-67-index reduction 
(%) comparing the Ki-67-index of the pretreatment tissue with the Ki-67-index of the 
corresponding surgical specimens. The error bars equal the 95% CI. 
By 18FDG-PET, a positive tumor response was recorded in 19/20 (95%) of the 
ISC-tumors and in 19/25 (76%) of the RC-tumors, p=0.11. 
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5 DISCUSSION 
This thesis included four prospective studies. The study on subepithelial 
lesions showed that the acquisition of pretreatment tumor tissue guided by 
endosonography has an important diagnostic value and clinical impact. By 
providing a stable diagnostic ground before therapy, this study challenges the 
current, suboptimal management of these lesions with unwarranted resections.  
Also the study performed on solid pancreatic lesions had a unique design 
including dual needle sampling of each lesion. No obvious benefit of EUS-
guided tissue acquisition was found. Nevertheless, the biopsy approach 
combined with routine fine-needle aspiration for cytology seemed 
advantageous in pancreatic neoplasms other than adenocarcinoma. This is new 
knowledge provided in a group of lesions not frequently studied before.   
In the last two studies including exclusively GISTs, the acquired tissue was 
highly accurate for the diagnosis as such but also, and importantly, for the 
pretreatment mutational analysis leading to a facilitated decision-making in 
down-sizing therapy. As compared with current literature, these studies 
provide the most accurate and profound characterization of GISTs prior to 
treatment. The presented ability to extract extensive information in 
pretreatment GISTs will have a probable impact on future guidelines of the 
field.   
The clinical implementation of the presented work-up concept could hopefully 
help in personalizing the care of patients with suspected pancreatic and 
gastrointestinal neoplasms, especially GIST. Below the results will be put into 
context and discussed with respect to the current literature. 
5.1 Interpretation of the accuracy in EUS-diagnostics 
There is a crucial aspect to keep in mind when interpreting the results of this 
thesis. Two separate procedures including several factors influence the final 
diagnostic accuracy of endosonography-guided sampling: a) The acquisition 
of the sample (the sample adequacy), in which the needle design is one factor 
among many others and b) The processing and assessment of the acquired 
sample, Figure 18. 
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As an example, the experience of the performing endosonographer, who needs 
to find and assess the target lesion, must not be underestimated140,141. Another 
example is small tumor size, which can decrease the chance of sampling 
success142. In the end, poor quality of any individual factor risks to finally result 
in a non-diagnostic (cyto)pathology report. Consequently, improved quality in 
the acquisition of the sample does not necessarily compensate for low 
cytopathology competence, and vice versa. Hence, when the accuracy of EUS-
FNB (and EUS-FNA) is mentioned in the following paragraphs of this 
discussion, a lot more than the needle design and the sampling maneuver is of 
importance. 
 
Figure 18. A flow chart symbolizing the complexity of obtaining a correct and 
conclusive diagnosis by EUS-guided sampling. Multiple factors (boxes in grey) 
influence both the adequacy of the sample and the assessment of the acquired sample, 
which both in the end affect the diagnostic accuracy. 
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5.2 Internal validity and confounding factors 
 
Internal validity measures the extent to which the studied independent variable, 
i.e. the intervention, actually causes the recorded value of the dependent 
variable, i.e. the study outcome. In the worst case scenario, a high proportion 
of the assumed causality is instead induced by a completely different (known 
or unknown) variable, which leads to a low internal validity. Such a variable 
is called a confounder.  
In the performance of the interventional study of Paper I-III (2012–2015) we 
had the ambition to obtain a high level of internal validity. We tried to 
minimize the number of potential confounders and the variability of all the 
factors influencing the final diagnostic accuracy, Figure 18. As an example, 
only endosonographers with sufficient experience were responsible for the 
inclusion of patients and the performance of EUS. Moreover, each lesion was 
sampled with both techniques – EUS-FNB and EUS-FNA. The sampling 
maneuver itself, including the applied needle suction and the needle 
movement, was also kept intact throughout the study. We used the identical 
study pathologist and cytopathologist during the complete study time (2012–
2015). They were also responsible for the assessment of the vast majority of 
the EUS-samples during the base-line period (2006–2011).  Finally, there were 
very few patients lost from follow-up, which also strengthens the internal 
validity. 
Nevertheless, it can be practically challenging, or even impossible, to 
accomplish complete conformity among potential confounders. Therefore, a 
number of such factors were separately tested with respect to the diagnostic 
accuracy (Supplementary Table, Paper I, and Table 3, Paper II).  
A weak point with respect to the internal validity was that the diagnosis in 
every single patient was not confirmed by surgical resection; histopathology 
was available in 40 % (Paper I) and in 69 % (Paper II). However, the scenario 
of having surgical specimens as the reference standard in all cases is probably 
unattainable in a cohort including many patients with severe malignancy.  
As a final remark, we decided to use only the reverse bevel FNB-needle 
throughout this research. FNB-needles with an alternative design might be as 
appropriate but they were not evaluated in this project. 
 44 
5.3 EUS-FNB in solid pancreatic lesions (Paper I) 
The diagnostic capacity of EUS-FNB was found comparable to EUS-FNA in 
the sampling of solid pancreatic lesions. We had hypothesized that the 
acquisition of whole tissue by EUS-FNB would be favorable (as compared 
with the aspiration of cells), especially when targeting tumors with the need 
for diagnostic immunostaining such as PNETs. 
It may be that the construction of the FNB-needle used in this thesis (reverse 
bevel) is not the optimal one for sampling of solid pancreatic lesions. In a 
recent study by Nayar and colleagues143 the accuracy of reverse bevel EUS-
FNB was found similar as in our study (~74 %), while the accuracy of another 
FNB-needle with an alternative design (opposing bevel) was found 
significantly higher (~92 %). Needles of different sizes (22 G/25 G/20 G) were 
used in the study and the majority of lesions were pancreatic adenocarcinomas. 
In some publications, including mostly PDACs, the sensitivity of EUS-FNA 
has been reported as high as 90 %144. However, one must keep in mind that 
immunostaining is not indispensable in PDACs145, which makes this high 
number almost unachievable in cohorts with a high distribution of neoplasms 
requiring immunostaining. The few studies reporting on populations 
exclusively consisting of PNETs suggest an accuracy of EUS-FNA around 80 
%146, which is comparable to the findings of Paper I. Regarding metastatic 
lesions, most reports have been retrospective without mandatory 
immunohistochemistry21,22.  
In our institution, the surgeons not routinely refer patients with SPLs for EUS. 
Therefore, the cohort of lesions studied in Paper I included a high number of 
PNETs and metastases. Hypothetically, this matter could have had a negative 
impact on the accuracy. Still, the accuracy of EUS-FNB was comparable to the 
result presented in the study by Nayar mentioned above143. The sensitivity of 
EUS-FNA was also in line with other publications107. These comparisons 
suggest that the dual needle sampling approach was not obviously 
disadvantageous for the outcome of sampling. 
 
We believe that Paper I contribute with new knowledge regarding the value of 
dual needle sampling as such. The approach is sparsely studied. Some groups 
have performed dual needle sampling, but without reporting the accuracy of 
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the combination of EUS-FNA and EUS-FNB147. To the best of our knowledge, 
only one study has analyzed, and found some benefit, by combining a 22 gauge 
FNB-needle with a 25 gauge open-tip FNA in the same SPL148. 
Whatever the reason for the recorded high accuracy of dual needle sampling, 
the approach is costly and increases the procedural time. Therefore, it should 
be considered only in selected cases having a high probability of harboring 
neoplasms other than PDAC or in centers without the access to ROSE.  
 
5.4 EUS-FNB in subepithelial lesions (Paper II) 
In line with the pre-study hypothesis, the EUS-FNB approach was found 
significantly superior to EUS-FNA in providing a conclusive diagnosis of 
subepithelial lesions. This large, prospective study fills an empty gap in the 
available EUS-literature since few studies evaluating EUS-FNB have been 
published 149 and only two exclusively on SELs150,151.  
 
In the first one by Kim and colleagues151, 22 patients were randomized to EUS-
FNB (n=12) or to EUS-FNA without ROSE (n=10). Lesions <20 mm were 
excluded. The diagnostic accuracy of EUS-FNA was recorded 20% and the 
accuracy of EUS-FNB was recorded 75%. The low number of patients in this 
study limits the value of comparison with our results. The accuracy of EUS-
FNA was also remarkably low. In the second one, a recent retrospective study 
by El Chafic and collaborators150, 106 SELs were included and punctured with 
EUS-FNA (n=91) or EUS-FNB (n=15). The needle size varied but was in most 
cases 22 gauge. The accuracy of EUS-FNA with ROSE was similar to our 
study (53%), while the accuracy of EUS-FNB including conclusive 
immunostaining was 87 %. Thus, these results were well in line with what was 
found in Paper II, even though the few EUS-FNB procedures performed make 
a direct comparison somewhat difficult.  
 
In Paper II, the superiority of EUS-FNB was clear in the subgroup of 
malignant neoplastic lesions such as GIST and leiomyosarcoma. The lack of 
statistical significance among the non-malignant cases was possibly due to the 
low number of study patients having a benign neoplastic lesion (n=13), such 
as a leiomyoma, or a non-neoplastic lesion (n=5), such as heterotopic tissue.  
 46 
 
 
Catch or no catch? A brown pelican (Pelecanus occidentalis) with a powerful beak is 
hunting fish in the Mexican gulf outside Estero Island, Southeast USA. Photo by the 
author. 
 
When testing for potential confounders, the lack of ROSE and a number of 
needle-passes below three showed a tendency to impact (reduce) the sensitivity 
of EUS-FNA (Table 3, Paper III). Therefore, a comparison EUS-FNB vs EUS-
FNA was performed in a subgroup excluding these cases. The diagnostic 
sensitivity of EUS-FNB was still found to be superior to that of EUS-FNA, 
28/30 (93%) vs 20/30 (66%), p=0.01. 
 
The sampling order (EUS-FNA first and EUS-FNB second; or vice versa) was 
not found to have an impact on the sensitivity of the respective technique 
(Table 3, Paper III). This finding strengthens the validity of the presented 
accuracy and sensitivity both regarding EUS-FNA and EUS-FNB.  
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5.5 The patient safety of EUS-FNB 
Physicians should never do more harm than good. Therefore, the patient safety 
in all diagnostic and therapeutic procedures is of high priority.  
The performance of reverse bevel EUS-FNB was found to be safe and related 
to a low adverse event rate in SPLs (1.4 %) and in SELs (1.2 %). These findings 
and numbers are comparable to the results of a few studies on SPL121,152 and 
on SELs121,151.  Tumor bleeding post sampling could have been a potential 
concern since, in general, both PNETs and GISTs are highly vascularized. 
No additional risk for events was observed due to the dual needle sampling 
approach as such. According to the available literature, this specific issue has 
not been addressed before148.    
Nevertheless, EUS-FNB is obviously not performed completely without risk 
in the pancreatic head since one patient in Paper I had a severe pancreatitis 
post-EUS. Therefore, ampullary lesions were excluded from dual needle 
sampling in Paper I. This means that the presented adverse event rate might 
not be representative for the lesions localized in this defined part of the 
pancreatic head.  
Certainly, the study patients were not actively contacted by phone to inquire 
for symptoms or problems after EUS. On the other hand, the development of 
adverse symptoms, as defined in this thesis, implies that the affected patients 
would have been in need of a hospital visit. Any such visit was screened for in 
the national medical file system (NPÖ). 
Finally, and as with the diagnostic accuracy, the occurrence of adverse events 
in EUS-procedures is related to more than one factor. Hence, it can be difficult 
to conclude if it is the actual needle or the maneuver that provokes the adverse 
event, not least in a dual needle study. 
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Probably not a patient friendly bite. A cottonmouth viper (Agkistrodon piscivorus) is 
targeting its prey in the high grass of the Corkscrew swamp sanctuary, Southwest 
Florida. Photo by Klara Hedenström. 
5.6 Clinical impact of EUS-FNB in subepithelial lesions 
(Paper II) 
The results of Paper II showed that the shift from routine EUS-FNA (2006–
2011) to EUS-FNB (2012–2015) resulted in a significant clinical impact 
demonstrated by the reduced need for additional diagnostic procedures post-
EUS. Likely, the complete benefit was thanks to the acquisition of FNB-tissue 
since EUS-FNA was non-diagnostic in all the study cases where EUS-FNB 
was also non-diagnostic.  
Paper II contributes with new valuable information. There are few works 
analyzing the clinical impact of EUS-guided tissue acquisition. The impact of 
the old generation biopsy needle (tru-cut) on clinical decision making was 
found moderate in an article published in 2011153. Since the tru-cut needle had 
a high rate of technical failures, this study is not the ideal one for comparison. 
In a retrospective article published in 2015, the authors found that the resection 
of a gastric leiomyoma could be avoided in 16/18 (89 %) patients thanks to a 
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high recorded accuracy of the reverse bevel EUS-FNB154. No extensive 
analysis of the clinical impact in all study subjects was however performed. 
In Paper II, the rate of benign lesions being sampled was somewhat higher in 
the base-line cohort (2006–2011) compared with the study cohort (2012–
2015). That might have had some influence on the detected difference between 
the cohorts. To compensate for that disparity in the distribution of lesions, the 
need for additional procedures was analyzed and found comparable in the 
subgroup of malignant lesions only. 
There is an important relevance of measuring the clinical impact. Additional 
diagnostic procedures post-EUS prolong the time to a conclusive diagnosis and 
risk to have a negative impact on patient well-being. Unnecessary follow-up is 
waste of money and resources. Unwarranted surgery is quite obviously related 
to patient morbidity and a diagnostic laparotomy seems obsolete in modern 
healthcare. 
5.7 Mutational analysis of FNB-tissue (Paper III) 
The FNB-tissue acquired from GIST was highly accurate for sequencing. This 
finding is significant since the preoperative work-up of GIST is not complete 
until the DNA-sequence of KIT and PDGFRA has been determined.  
The unveiling of mutations in KIT and PDGFRA has a so called theranostic 
dual implication72,155. First, the therapy of GISTs is hugely impacted by the 
mutation profile of individual tumors. Importantly, the efficacy of tyrosine 
kinase inhibitor therapy can be firmly predicted only by knowing the status of 
KIT and PDGFRA44. Not less important from a surgical point of view, the risk 
for tumor rupture during resection is strongly related to mutations in KIT exon 
11156. Second, the prognosis of a patient affected by a GIST will be precise and 
reliable only by the inclusion of the mutation profile79,157. 
The feasibility of sequencing using EUS-FNA-samples has been explored only 
in two small, retrospective case-series158,159 and in a minor retrospective cohort 
of twenty patients155. This thesis (Paper III/IV) is the first publication to present 
a prospective and systematic sequencing of GISTs. 
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The aim of Paper III was to investigate the feasibility of mutational analysis 
using tissue harvested by EUS-guidance. The finding that EUS-FNB actually 
provides the tissue needed for accurate sequencing in most cases was 
strengthened by the fact the mutation profile was re-analyzed and confirmed 
in the resection specimens of all resected patients (n=27). 
In Paper III, Sanger sequencing was the method used. The amount of tumor 
cells required in Sanger analysis is higher than in NGS, which is currently the 
primary method used (Paper IV). Consequently, in 2018 it can expected that 
almost any yield of FNB-tissue will be adequate for successful sequencing.   
5.8 The Ki-67-index of GISTs in FNB-tissue (Paper III) 
The Ki-67-index determined in pretreatment GIST-tissue corresponded well 
with the Ki-67-index assessed in the corresponding surgical specimens of 
patients not treated with down-sizing therapy. 
Certainly, the Ki-67-index is not included in the validated NIH risk score, 
which instead uses the mitotic index (MI) for the determination of the tumor 
proliferation rate57. Nevertheless, the assessment of the pretreatment Ki-67-
index is not futile, since the tumor proliferation rate is more important than 
tumor size with respect to the prognostic risk72.  
 
Other groups have investigated the Ki-67-index as an alternative method to MI 
but only in surgical specimens of GIST. The level of the Ki-67-index was 
shown to strongly correlate with the prognosis37,60,62. In the study by Nilsson 
and collaborators37, the maximum Ki-67-index was proven to be an 
independent risk indicator in 251 patients with GIST. Given a fixed tumor size 
of 5 cm, each percentage point increase in the maximum Ki-67-index was 
associated with a 5 % increased risk of dying. A Ki-67-based GIST risk score 
(GRS) was constructed (GRS = maximum tumor diameter (cm) + maximum 
Ki-67-index). A GRS > 7 was found to be associated with an increased risk of 
dying within five years. The results of Paper III suggests that the GRS-score 
could be applied also in pretreatment EUS-FNB-tissue. 
 
In an interesting study, Kemmerling and colleagues assessed both the Ki-67-
index and the MI in 154 specimens of documented GISTs62. They showed that 
the proliferation rate measured by the Ki-67-index actually predicted the 
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recurrence and metastasis rate of GIST better than the MI. Moreover, a linear 
regression model was elaborated for the reliable prediction of the MI based on 
the Ki-67-index (MI = f (x) = 0.084x – 6.328), where x is the Ki-67-index 
expressed as the number of Ki-67 positive nuclei per mm2. Using this equation, 
the authors found that a Ki-67-index of 135 positive nuclei/ mm2 equaled an 
MI of 5. Thereby this Ki-67-index could be used as the surrogate cut-off value 
for a high mitotic index, which means increased risk. A similar conversion 
model and equation could probably be elaborated for EUS-FNB-tissue. The 
publication by Kemmerling et al stresses that the Ki-67-index assessed in 
pretreatment tissue justifies attention as a promising and clinically useful risk 
indicator in GIST.    
 
Apparently the MI is not the appropriate method for the assessment of tumor 
proliferation rate in pretreatment tissue acquired by EUS. In our study, the 
acquired FNB-tissue had a maximal size at microscopy of 38 high-power fields 
(hpf, 1 hpf = 0.16 mm2) while a maximum of 11 hpf was counted in a study 
analyzing twelve EUS-biopsies154.  A minimum of 50 hpf is required for the 
adequate calculation of the MI57. 
Potentially, the most valuable application of Ki-67-indexing in pretreatment 
GIST-tissue would be the estimation of the true tumor proliferation rate in 
patients intended for preoperative down-sizing therapy. Thus, we also 
compared the Ki-67-index of pretreatment FNB-tissue with the Ki-67-index of 
the corresponding surgical specimens in patients subjected to down-sizing 
imatinib. By performing this comparison, we could demonstrate that the Ki-
67-index in surgical specimens is significantly lower than in FNB-tissue; 
provided a sensitive mutation (Figure 3, Paper III). This finding implicates that 
the calculated NIH risk score will be falsely low in surgical specimens. In 
addition, these patients cannot be properly evaluated for adjuvant therapy.  
The presented method could also serve as a marker for the efficacy of down-
sizing imatinib therapy. Since 18FDG-PET is an expensive method160,161; the 
Ki-67-indexing of repeated EUS-biopsies would be an attractive alternative by 
which the therapy response could be evaluated. 
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5.9 Pretreatment sequencing and down-sizing imatinib 
During the study time frame (2014–2017) of Paper IV, immediate, 
pretreatment sequencing was successful in all but two samples resulting in the 
incorrect down-sizing management of only 2/59 (3%) patients. Given the 
obvious risk for ineffective treatment and the significant risk for side-effects, 
the indication for such a work-up in GIST seems strong. 
To the best of our knowledge, the current work is the first study presenting 
systematic and extensive genomic data of GISTs at an early preoperative stage 
with clear impact upon the clinical management. The study required the 
collaboration of multiple departments and the combination of several 
diagnostic procedures and advanced analyses.  
The categorization of different variants of mutations with respect to the 
expected tumor response (Table 1, Paper IV), and thereby the definition of a 
correct down-sizing therapy, was based on guidelines and relevant literature of 
the field78. The best therapy strategy remains to be decided for certain variants 
of mutations in KIT and PDGFRA. Therefore, studies are ongoing, such as the 
ALT-GIST trial (NCT02365441), which is evaluating alternating imatinib and 
regorafenib in advanced GIST. 
 
The level of effect induced by imatinib in primary KIT exon 13-mutants (p. 
K642E) is not firmly elucidated because the variant is uncommon. Stable 
disease is probably a more common result than partial response according to a 
review by Bachet et al80. After consideration, we decided to regard primary 
KIT exon 13-mutants as resistant to imatinib in Paper III. This might have been 
erroneous since some tumors actually do respond. In Paper IV we applied a 
more generous interpretation of the literature and considered primary KIT exon 
13-mutants as sensitive to standard dose imatinib. If regarding KIT exon 13 (p. 
K642E) as non-sensitive the value of pretreatment sequencing would be 
actually even higher.  
 
Another complicated example is the KIT exon 11 (p. L576P)-mutant. Noujaim 
and colleagues analyzed tumors of five patients diagnosed with KIT exon 11 
(p. L576P)-mutated GISTs162. They noticed a favorable effect of imatinib with 
partial response (>30 % size-reduction) in two of these five patients. Therefore, 
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they proposed that imatinib can still be used as the first-line treatment also in 
p. L576P-mutants. This conclusion is however contradicted by an in vitro 
study, which found that p. L576P-mutants required a 10-fold higher dose of 
imatinib concentration to obtain the same response as mutants fully sensitive 
to imatinib163. In the end, we decided to regard KIT exon 11 p.(L576P)-mutants 
as non-sensitive to imatinib. 
 
Whatever may be the optimal categorization of mutations, the pretreatment 
clarification of the mutation profile supports the responsible clinician with 
valuable theranostic information. Moreover, early reappraisal of the therapy 
can considered in cases with uncertain sensitivity to imatinib.   
 
 
Surgery of a gastrointestinal stromal tumor. The image shows the tumor of a 62-year 
old man initially suffering from a 10 cm GIST in the gastric fundus with tumor growth 
on the diaphragm. Up-front surgical resection was not possible. After pretreatment 
sequencing detecting a KIT exon 11 V558-deletion, the patient was initiated on 12 
months of down-sizing imatinib. The tumor reduced in size and could be resected en 
bloc with a limited resection of the diaphragm. Photo by the author. 
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5.10 Tumor response to down-sizing imatinib 
The tumor response induced by down-sizing standard dose imatinib was 
improved in the group of GISTs subjected to pretreatment mutational analysis 
during the study time frame (2012–2015). The reason for this was most 
probably that GIST-mutants with a reduced sensitivity or complete resistance 
to imatinib were identified before the initiation of therapy. Instead these 
patients could be offered an alternative therapy, such as sunitinib, or up-front 
surgery. 
A challenging group with respect to pretreatment sequencing is distal, small-
intestinal GISTs since this region is not within reach for EUS. In these cases, 
the acquisition of tissue guided by transabdominal ultrasound could be an 
alternative and safe method164. Small-intestinal GISTs of small size could still 
be problematic but few of those would however require down-sizing therapy.  
The imatinib dose in the setting of down-sizing therapy is not actually 
standardized or well determined. Imatinib in different dose and duration has 
been evaluated in some other studies87,88,165. Rutkowski et al initiated imatinib 
400 mg daily in all patients, while Wang and colleagues used imatinib 600 mg 
daily in all patients. Nonetheless, we applied the term “standard dose” on the 
dose of imatinib 400 mg daily since this is the dose recommended in the 
adjuvant setting72.  
There are advantages and shortcomings with all methods used for the 
evaluation of tumor response induced by imatinib therapy. As some examples, 
the base-line signal of 18FDG-PET can be negative in GIST166, the appropriate 
method for PET-signal measurement is a matter of debate136, and 18FDG-PET 
does not predict progression free survival167. Tumors actually responding to 
therapy do not necessarily reduce in size on CT scan but rather in density168. 
This was also the reason why the results of three different methods (CT scan, 
18FDG-PET, and the Ki-67-index) was presented. Pretreatment sequencing can 
probably not replace the evaluation by CT scan. The imatinib effect needs to 
be monitored in some way and measurement of the tumor shrinkage is 
important for the planning of surgery. However, pretreatment sequencing has 
the potential to replace the evaluation with 18FDG-PET; at least in regular KIT 
exon 11-mutants, in which the effect of imatinib is high.         
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A major limitation of Paper IV worth mentioning is that the outcome of surgery 
and the recurrence free survival was not analyzed. A larger (multi-centric, 
randomized) study including a high number of patients, would be required to 
show an effect on these parameters by down-sizing therapy based on 
pretreatment sequencing. Even so, the results of Paper IV clearly illuminates 
the advantages of mutation-based, preoperative therapy of GIST. 
5.11 The external validity of the results 
The conclusions of a single research project should always be interpreted with 
some caution since the results may not always be generalized. Study design 
and actions undertaken to prevent confounding factors may increase the degree 
of internal validity but limit the so called external validity, i.e. the ability to 
accomplish the same results in other centers. Nevertheless, the external validity 
of the presented results is probably rather high.  
All the study patients of this thesis were referred for a clinical EUS and no 
examination was performed for research purpose only. The number of 
exclusion criteria was few. Thus, the level of patient selection bias was 
probably quite low in the papers presented. The patient population studied in 
this thesis should be fairly representative for a university hospital handling 
upper GI neoplasms.  
The major procedures and processes did not profoundly differ from what is 
common practice within the field of EUS-based diagnostics. Standard 
equipment was used and should be available for purchase in most countries 
where EUS is performed. The FNB-sampling technique applied in this thesis 
is not dramatically different from routine EUS-FNA.  
We used a conservative approach regarding the results of (cyto)pathology and 
the categorization of samples. A more generous approach would have resulted 
in a higher accuracy and sensitivity for tumors requiring diagnostic 
immunostaining. Meanwhile we had access to (cyto)pathology expertise with 
long experience in the assessment of EUS-samples and that may not be the fact 
in all centers. 
The start-up and organization of a new EUS-facility requires some effort and 
perfect results cannot be expected momentarily since the quality of all 
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procedures included in the process need to be reasonably high. Therefore, 
results comparable to the ones presented in this thesis can only be expected in 
EUS-centers with an equivalent level of experience. 
Adding DNA-sequencing of pretreatment tumor tissue as yet another 
procedure on top of routine work-up might of course not be feasible in all 
institutions dealing with EUS. Such management requires the access to an 
advanced laboratory and skilled geneticists. 
5.12 Limitations 
Specific limitations in each individual study of this thesis has been discussed 
above.  
A limitation regarding the research project as a whole was that it was 
performed in a single-center setting. Another general limitation was that the 
project spanned over a long period of time. It cannot be ruled out that the 
technical development of imaging and the increasing experience of the 
collaborators involved in the project might have had some influence upon the 
results presented. 
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6 CONCLUSIONS 
• In solid pancreatic lesions, the work-up with 
endosonography-guided fine needle biopsy sampling (EUS-
FNB) is patient safe, but not superior to fine needle aspiration 
(EUS-FNA) for cytology. The performance of both 
modalities could be considered in lesions suspicious for 
neuroendocrine tumors or metastases.   
 
• In subepithelial lesions, EUS-FNB is patient safe and has a 
significantly higher diagnostic accuracy compared with EUS-
FNA. EUS-FNB also leads to the reduced need for additional 
diagnostic procedures after EUS including diagnostic, 
surgical resections. 
 
• The preoperative diagnostics of GISTs was previously 
challenging with a poor accuracy. Pretreatment EUS-FNB is 
highly accurate for the conclusive diagnosis of GISTs already 
at the preoperative stage. 
 
• In GISTs, the acquired EUS-FNB-tissue is well aimed for fast 
and accurate pretreatment genetic profiling of KIT and 
PDGFRA, which can be used to guide down-sizing therapy 
and reduce the need for expensive 18FDG-PET. 
 
• In GISTs, the tumor response to down-sizing, standard dose 
imatinib will be more predictable if pretreatment sequencing 
is performed to select the appropriate patients. 
 
• In GISTs, the pretreatment EUS-FNB-tissue is adequate for 
the reliable assessment of the tumor proliferation rate (Ki-67-
index), which risks to be falsely low in surgical specimens of 
patients treated with down-sizing therapy. 
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7 FUTURE PERSPECTIVES 
Further and refined studies are needed to optimize the EUS-diagnostics and 
improve the care of all patients affected by pancreatic malignancies, 
mesenchymal tumors, and other types of neoplasms. 
 
Future direction? Tree tops stretching towards the sky, Big Cypress National 
Preserve, Southwest Florida. Photo by Klara Hedenström.  
During the study time frame (2012–2015), patients with other lesions such as 
lymph nodes and adrenal tumors were also enrolled as study subjects and 
sampled with the dual needle approach. By combining these cases with all the 
cases of this thesis and all the cases sampled in 2006–2011, we plan to perform 
an extensive study on the diagnostic accuracy of EUS. This study is planned 
to be part of a future PhD-project. 
Regarding pancreatic neuroendocrine tumors, the prognostic risk59 and the 
operability169 strongly correlate with the tumor proliferation rate (Ki-67-
index). Ki-67-staining and systematic measurement of the Ki-67-index in the 
acquired FNB-tissue and the FNA-samples (Paper I) could be the focus of a 
future project.  
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As described, the experience of the endosonographer is a factor influencing the 
quality of EUS-diagnostics. However, it is poorly studied what factors that 
actually influence the EUS learning process and the technical skills of the 
endosonographer in training. To address these questions we initiated in 2014 a 
study (GEUSP – Global assessment of the EUS Performance skills), which is 
currently running and recruiting study subjects. At present, we have enrolled 
ten endosonographers together performing a total of 105 EUS-examinations. 
This project is open for international collaboration. 
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APPENDIX 
Table NIH consensus prognostic risk criteria for GIST  
NIH Risk Tumor size (cm) Mitotic index (per 50 hpf) 
Very low risk <2 <5 
Low risk 2-5 <5 
Intermediate risk <5 6-10 
 5-10 <5 
High risk >5 >5 
 >10 any mitotic index 
  any size >10 
 
Table DNA-codons coding for the respective amino acids  
Amino acid Abbreviation Letter Codon (base triplet) 
Alanine Ala A GCT, GCC, GCA, GCG 
Arginine Arg R CGT, CGC, CGA, CGG, AGA, AGG 
Aspargine Asn N AAT, AAC 
Aspartic acid Asp D GAT, GAC 
Cysteine Cys C TGT, TGC 
Glutamine Gln Q CAA, CAG 
Glutamic acid Glu E GAA, GAG 
Glycine Gly G GGT, GGC, GGA, GGG 
Histidine His H CAT, CAC 
Isoleucine Ile I ATT, ATC, ATA 
Leucine  Leu L TTA, TTG, CTT, CTC, CTA, CTG 
Lysine Lys K AAA, AAG 
Methionine Met M ATG 
Phenylalanine Phe F TTT, TTC 
Proline Pro P CCT, CCC, CCA, CCG 
Serine Ser S TCT, TCC, TCA, TCG, AGT, AGC 
Threonine Thr T ACT, ACC, ACA, ACG 
Tryptophan Trp W TGG 
Tyrosine Tyr Y TAT, TAC 
Valine Val V GTT, GTC, GTA, GTG 
 
